I agree CYDY is significantly undervalued and than
Post# of 148184
One note is the royalty out to Progenics and AbbVie is now reduced to 'up to 10.5%' from the previous 12.5%. This changed in the quarterly filings last year sometime and can be found in the middle of page 7 on the most recent 10-K filing. 2% seems minor, but in your example below of 30K patients, this increases the share price from $3.15 to $3.67 (16.5% increase) given your same assumptions.